Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

The microbiome in bronchiectasis.

Richardson H, Dicker AJ, Barclay H, Chalmers JD.

Eur Respir Rev. 2019 Sep 4;28(153). pii: 190048. doi: 10.1183/16000617.0048-2019. Print 2019 Sep 30.

2.

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

Loebinger MR, Polverino E, Blasi F, Elborn SJ, Chalmers JD, Tiddens HA, Goossens H, Tunney M, Zhou W, Angyalosi G, Hill AT, Haworth CS; iBEST-1 Trial Team.

Pulm Pharmacol Ther. 2019 Aug 18;58:101834. doi: 10.1016/j.pupt.2019.101834. [Epub ahead of print]

PMID:
31433997
3.

Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.

Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N, Taylor SL, Martin ML, Burr LD, Wong C, Altenburg J.

Lancet Respir Med. 2019 Aug 9. pii: S2213-2600(19)30191-2. doi: 10.1016/S2213-2600(19)30191-2. [Epub ahead of print]

PMID:
31405828
4.

The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.

Laska IF, Crichton ML, Shoemark A, Chalmers JD.

Lancet Respir Med. 2019 Aug 9. pii: S2213-2600(19)30185-7. doi: 10.1016/S2213-2600(19)30185-7. [Epub ahead of print]

PMID:
31405826
5.

Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry.

Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, Trivedi S, Rajagopala S, D'Souza G, Padmanabhan A, Baburao A, Mahesh PA, Ghewade B, Nair G, Jindal A, Jayadevappa GDH, Sawhney H, Sarmah KR, Saha K, Anantharaj S, Khanna A, Gami S, Shah A, Shah A, Dutt N, Garg H, Vyas S, Venugopal K, Prasad R, Aleemuddin NM, Karmakar S, Singh V, Jindal SK, Sharma S, Prajapat D, Chandrashekaria S, McDonnell MJ, Mishra A, Rutherford R, Ramanathan RP, Goeminne PC, Vasudev P, Dimakou K, Crichton ML, Jayaraj BS, Kungwani R, Das A, Sawhney M, Polverino E, Torres A, Gulecha NS, Shteinberg M, De Soyza A, Mangala A, Shah P, Chauhan NK, Jajodia N, Singhal A, Batra S, Hasan A, Limaye S, Salvi S, Aliberti S, Chalmers JD.

Lancet Glob Health. 2019 Sep;7(9):e1269-e1279. doi: 10.1016/S2214-109X(19)30327-4.

6.

Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?

Laska IF, Chalmers JD.

Eur Respir J. 2019 Jul 18;54(1). pii: 1901213. doi: 10.1183/13993003.01213-2019. Print 2019 Jul. No abstract available.

PMID:
31320480
7.

Same meat, different gravy: ignore the new names of mycobacteria.

Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, Floto RA, Garcia MJ, Hoefsloot W, Koh WJ, Lange C, Loebinger M, Maurer FP, Morimoto K, Niemann S, Richter E, Turenne CY, Vasireddy R, Vasireddy S, Wagner D, Wallace RJ Jr, Wengenack N, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900795. doi: 10.1183/13993003.00795-2019. Print 2019 Jul. No abstract available.

PMID:
31296783
8.

Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.

Sibila O, Perea L, Cantó E, Shoemark A, Cassidy D, Smith AH, Suarez-Cuartin G, Rodrigo-Troyano A, Keir HR, Oriano M, Ong S, Vidal S, Blasi F, Aliberti S, Chalmers JD.

Thorax. 2019 Sep;74(9):835-842. doi: 10.1136/thoraxjnl-2018-212895. Epub 2019 Jul 5.

PMID:
31278172
9.

Pregnancy Zone Protein is Associated with Airway Infection, Neutrophil Extracellular Trap Formation and Disease Severity in Bronchiectasis.

Finch S, Shoemark A, Dicker AJ, Keir HR, Smith A, Ong S, Tan B, Choi JY, Fardon TC, Cassidy D, Huang JTJ, Chalmers JD.

Am J Respir Crit Care Med. 2019 Jul 2. doi: 10.1164/rccm.201812-2351OC. [Epub ahead of print]

PMID:
31264895
10.

Response.

Chalmers JD.

Chest. 2019 Jun;155(6):1302-1303. doi: 10.1016/j.chest.2019.02.316. No abstract available.

PMID:
31174643
11.

A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.

Shoemark A, Cant E, Carreto L, Smith A, Oriano M, Keir HR, Perea L, Canto E, Terranova L, Vidal S, Moffitt K, Aliberti S, Sibila O, Chalmers JD.

Eur Respir J. 2019 Jun 13;53(6). pii: 1900303. doi: 10.1183/13993003.00303-2019. Print 2019 Jun.

PMID:
31151955
12.

Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis.

Sibila O, Laserna E, Shoemark A, Keir HR, Finch S, Rodrigo-Troyano A, Perea L, Lonergan M, Goeminne PC, Chalmers JD.

Am J Respir Crit Care Med. 2019 Jul 1;200(1):33-41. doi: 10.1164/rccm.201809-1651OC.

PMID:
31109172
13.

Rheumatoid arthritis-associated bronchiectasis - Authors' reply.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2019 May 18;393(10185):2036. doi: 10.1016/S0140-6736(19)30012-1. No abstract available.

PMID:
31106746
14.

Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial.

Chalmers JD, Crichton ML, Brady G, Finch S, Lonergan M, Fardon TC.

BMC Pulm Med. 2019 May 6;19(1):85. doi: 10.1186/s12890-019-0856-0.

15.

Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.

VanDevanter DR, Gonda I, Dahms J, Cipolla D, Davis AM, Chalmers JD, Froehlich J.

Clin Microbiol Infect. 2019 Apr 26. pii: S1198-743X(19)30194-6. doi: 10.1016/j.cmi.2019.04.017. [Epub ahead of print]

PMID:
31035017
16.

Bronchiectasis Guidelines-Recommendations Into Practice.

Redondo M, Chalmers JD.

Arch Bronconeumol. 2019 Jun;55(6):286-288. doi: 10.1016/j.arbres.2018.10.012. Epub 2019 Apr 10. English, Spanish. No abstract available.

17.

Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition.

Keir HR, Fong CJ, Crichton ML, Barth P, Chevalier E, Brady G, Kennedy G, Zimmermann J, Bruijnzeel PLB, Dicker AJ, Chalmers JD.

ERJ Open Res. 2019 Mar 25;5(1). pii: 00252-2018. doi: 10.1183/23120541.00252-2018. eCollection 2019 Feb.

18.

A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.

Crichton ML, Aliberti S, Chalmers JD.

Eur Respir Rev. 2019 Mar 14;28(151). pii: 180108. doi: 10.1183/16000617.0108-2018. Print 2019 Mar 31.

19.

The economic burden of bronchiectasis - known and unknown: a systematic review.

Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, Upton A, Wichmann K, Xu W, Chalmers JD.

BMC Pulm Med. 2019 Feb 28;19(1):54. doi: 10.1186/s12890-019-0818-6.

20.

Reply: More on Causal Inference Studies.

Lederer DJ, Bell SC, Smyth AR, Chalmers JD.

Ann Am Thorac Soc. 2019 May;16(5):646. doi: 10.1513/AnnalsATS.201901-070LE. No abstract available.

21.

Challenges in severe community-acquired pneumonia: a point-of-view review.

Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG.

Intensive Care Med. 2019 Feb;45(2):159-171. doi: 10.1007/s00134-019-05519-y. Epub 2019 Jan 31. Review.

PMID:
30706119
22.

British Thoracic Society guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher WP, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

BMJ Open Respir Res. 2018 Dec 28;5(1):e000348. doi: 10.1136/bmjresp-2018-000348. eCollection 2018.

23.

Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.

Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE.

Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Erratum in: Lancet Respir Med. 2019 Jan 25;:.

PMID:
30658914
24.

The evolution of the European Respiratory Journal: volume 2.

Chalmers JD, Kolb M.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802459. doi: 10.1183/13993003.02459-2018. Print 2019 Jan. No abstract available.

PMID:
30655453
25.

British Thoracic Society Guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

Thorax. 2019 Jan;74(Suppl 1):1-69. doi: 10.1136/thoraxjnl-2018-212463. No abstract available.

PMID:
30545985
26.

The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD.

Flynn RWV, MacDonald TM, Chalmers JD, Schembri S.

Respir Res. 2018 Dec 12;19(1):249. doi: 10.1186/s12931-018-0960-3.

27.

Economic burden of bronchiectasis in Germany.

Diel R, Chalmers JD, Rabe KF, Nienhaus A, Loddenkemper R, Ringshausen FC.

Eur Respir J. 2019 Feb 28;53(2). pii: 1802033. doi: 10.1183/13993003.02033-2018. Print 2019 Feb.

PMID:
30523162
28.

New Insights Into the Epidemiology of Bronchiectasis.

Chalmers JD.

Chest. 2018 Dec;154(6):1272-1273. doi: 10.1016/j.chest.2018.08.1051. No abstract available.

PMID:
30526964
29.

ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training.

Aliberti S, Farr A, Tabin N, Blasi F, Torres A, Woodhead M, Migliori GB, Sotgiu G, Dimopoulos G, Chalmers JD, Ringshausen FC, Loebinger MR, Read R, Rohde G.

Breathe (Sheff). 2018 Dec;14(4):269-275. doi: 10.1183/20734735.026218.

30.

Quality control for multiple breath washout tests in multicentre bronchiectasis studies: Experiences from the BRONCH-UK clinimetrics study.

O'Neill K, Lakshmipathy GR, Ferguson K, Cosgrove D, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, DeSoyza A, Hurst JR, Bradbury I, Elborn JS, Bradley JM.

Respir Med. 2018 Dec;145:206-211. doi: 10.1016/j.rmed.2018.10.030. Epub 2018 Nov 1.

PMID:
30509710
31.

A comprehensive approach to lung function in bronchiectasis.

Radovanovic D, Santus P, Blasi F, Sotgiu G, D'Arcangelo F, Simonetta E, Contarini M, Franceschi E, Goeminne PC, Chalmers JD, Aliberti S.

Respir Med. 2018 Dec;145:120-129. doi: 10.1016/j.rmed.2018.10.031. Epub 2018 Nov 2.

PMID:
30509700
32.

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration.

Aliberti S, Polverino E, Chalmers JD, Altenburg J, Shteinberg M, Goeminne PC, Welte T, Shoemark A, Almagro M, Blasi F; EMBARC Clinical Research Collaboration.

Eur Respir J. 2018 Nov 29;52(5). pii: 1802074. doi: 10.1183/13993003.02074-2018. Print 2018 Nov. No abstract available.

PMID:
30498055
33.

Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial.

Chalmers JD, Djamin RS, Schouten M, Keir HR, Tan B, Aerts JGJV, Huang JT, van der Eerden M.

ERJ Open Res. 2018 Nov 12;4(4). pii: 00136-2018. doi: 10.1183/23120541.00136-2018. eCollection 2018 Oct.

34.

Bronchiectasis.

Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ.

Nat Rev Dis Primers. 2018 Nov 15;4(1):45. doi: 10.1038/s41572-018-0042-3. Review.

PMID:
30442957
35.

How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis.

Terranova L, Oriano M, Teri A, Ruggiero L, Tafuro C, Marchisio P, Gramegna A, Contarini M, Franceschi E, Sottotetti S, Cariani L, Bevivino A, Chalmers JD, Aliberti S, Blasi F.

Int J Mol Sci. 2018 Oct 20;19(10). pii: E3256. doi: 10.3390/ijms19103256.

36.

Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis.

Mac Aogáin M, Tiew PY, Lim AYH, Low TB, Tan GL, Hassan T, Ong TH, Pang SL, Lee ZY, Gwee XW, Martinus C, Sio YY, Matta SA, Ong TC, Tiong YS, Wong KN, Narayanan S, Au VB, Marlier D, Keir HR, Tee A, Abisheganaden JA, Koh MS, Wang Y, Connolly JE, Chew FT, Chalmers JD, Chotirmall SH.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):842-853. doi: 10.1164/rccm.201807-1355OC.

PMID:
30265843
37.

A systematic review of clinical trial registration in major respiratory journals 2010-2018.

Suntila NSM, Smith A, Al-Dabbagh Y, Chalmers JD.

Eur Respir J. 2018 Dec 6;52(6). pii: 1801491. doi: 10.1183/13993003.01491-2018. Print 2018 Dec. No abstract available.

PMID:
30262578
38.

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.

Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, Suissa S, Adjei AA, Akdis CA, Azoulay É, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL.

Ann Am Thorac Soc. 2019 Jan;16(1):22-28. doi: 10.1513/AnnalsATS.201808-564PS. No abstract available. Erratum in: Ann Am Thorac Soc. 2019 Feb;16(2):283.

39.

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2018 Sep 8;392(10150):880-890. doi: 10.1016/S0140-6736(18)31767-7. Review.

40.

The future of accreditation of continuing medical education (CME)-continuing professional development (CPD) in Europe: harmonisation through dialogue and consensus.

de Andrade F, Griebenow R, Costello RW, Guenova M, Schaefer R, Chalmers JD, Tichelli A, Raguz D, Stein J.

J Eur CME. 2018 Sep 3;7(1):1506202. doi: 10.1080/21614083.2018.1506202. eCollection 2018.

41.

Treatable traits in bronchiectasis.

Boaventura R, Sibila O, Agusti A, Chalmers JD.

Eur Respir J. 2018 Sep 6;52(3). pii: 1801269. doi: 10.1183/13993003.01269-2018. Print 2018 Sep. No abstract available.

PMID:
30190263
42.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

43.

Get together to increase awareness in bronchiectasis: a report of the 2nd World Bronchiectasis Conference.

Aliberti S, Chalmers JD.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):28. doi: 10.1186/s40248-018-0138-3. eCollection 2018. No abstract available.

44.

Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis.

Contarini M, Shoemark A, Rademacher J, Finch S, Gramegna A, Gaffuri M, Roncoroni L, Seia M, Ringshausen FC, Welte T, Blasi F, Aliberti S, Chalmers JD.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):26. doi: 10.1186/s40248-018-0143-6. eCollection 2018. Review.

45.

A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk.

McDonnell MJ, O'Toole D, Ward C, Pearson JP, Lordan JL, De Soyza A, Loebinger M, Chalmers JD, Laffey JG, Rutherford RM.

Respir Med. 2018 Aug;141:132-143. doi: 10.1016/j.rmed.2018.06.031. Epub 2018 Jun 30. Review.

PMID:
30053958
46.

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.

Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD.

Eur Respir J. 2018 Sep 15;52(3). pii: 1800328. doi: 10.1183/13993003.00328-2018. Print 2018 Sep. Review.

PMID:
30049739
47.

Bronchiectasis: a case-based approach to investigation and management.

Contarini M, Finch S, Chalmers JD.

Eur Respir Rev. 2018 Jul 11;27(149). pii: 180016. doi: 10.1183/16000617.0016-2018. Print 2018 Sep 30. Review.

48.

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.

Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S; GLIMP.

Eur Respir J. 2018 Aug 9;52(2). pii: 1701190. doi: 10.1183/13993003.01190-2017. Print 2018 Aug.

PMID:
29976651
49.

The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis.

Goeminne PC, Cox B, Finch S, Loebinger MR, Bedi P, Hill AT, Fardon TC, de Hoogh K, Nawrot TS, Chalmers JD.

Eur Respir J. 2018 Jul 27;52(1). pii: 1702557. doi: 10.1183/13993003.02557-2017. Print 2018 Jul.

PMID:
29903857
50.

Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study.

Mac Aogáin M, Chandrasekaran R, Lim AYH, Low TB, Tan GL, Hassan T, Ong TH, Hui Qi Ng A, Bertrand D, Koh JY, Pang SL, Lee ZY, Gwee XW, Martinus C, Sio YY, Matta SA, Chew FT, Keir HR, Connolly JE, Abisheganaden JA, Koh MS, Nagarajan N, Chalmers JD, Chotirmall SH.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800766. doi: 10.1183/13993003.00766-2018. Print 2018 Jul.

Supplemental Content

Loading ...
Support Center